Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy

Journal of Pharmaceutical Sciences

Volumn 104, Issue 1, 2015, Pages 72-80

  Lim, Sung Mook ^a   Eom, Ha Na ^a   Jiang, Hai Hua ^a   Sohn, Minji ^a   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Acylation; Exendin 4; Immunogenicity; Microspheres; PEGylation; Peptide delivery; PLGA; Polymeric drug delivery systems

Indexed keywords

EXENDIN 4; GLUCOSE; MICROSPHERE; PEPTIDE; POLYGLACTIN; POLYMER; ANTIBODY; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; INCRETIN; LACTIC ACID; MACROGOL DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SUSPENSION; VENOM;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIDIABETIC ACTIVITY; ARTICLE; BIODEGRADATION; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; ENCAPSULATION; EVAPORATION; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; MALE; METABOLIC PARAMETERS; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG FORMULATION; DRUG HYPERSENSITIVITY; HALF LIFE TIME; IMMUNOLOGY; MUTANT MOUSE STRAIN; PHARMACOKINETICS; RANDOMIZATION; SOLUBILITY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSPENSION; THERAPEUTIC USE;

ACYLATION; ANIMALS; ANTIBODIES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; DRUG HYPERSENSITIVITY; HALF-LIFE; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MALE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICROSPHERES; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS; VENOMS;

EID: 84919798335     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24238     Document Type: Article

References (30)

1. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. 1992. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405.
2. Todd JF, Bloom SR. 2007. Incretins and other peptides in the treatment of diabetes. Diabet Med 24:223-232.
3. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR. 2001. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-161.
4. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. 2003. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089.
5. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. 1993. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655.
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276.
7. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. 2005. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62(2):173-181.
8. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group. 2008. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 372:1240-1250.
9. Kwak HH, Shim WS, Hwang S, Son MK, Kim YJ, Kim TH, Yoon ZH, Youn HJ, Lee GI, Kang SH, Shim CK. 2009. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm Res 26:2504-2512.
10. Antonelli G. 1997. In vivo development of antibody to interferons: An update to 1996. J Interferon Cytokine Res 17:S39-46.
11. Jiang W, Schwendeman SP. 2001. Stabilization and controlled release of bovine serum albumin encapsulated in poly (D, L-lactide) and poly (ethylene glycol) microsphere blends. Pharm Res 18:878-885.
12. Zhu G, Schwendeman SP. 2000. Stabilization of proteins encapsulated in cylindrical poly (lactide-co-glycolide) implants: Mechanism of stabilization by basic additives. Pharm Res 17:351-357.
13. Gedulin BR, SmithP, Prickett KS, TryonM, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA. 2005. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48:1380-1385.
14. Zhang Y, Sophocleous AM, Schwendeman SP. 2009. Inhibition of peptide acylation in PLGA microspheres with water-soluble divalent cationic salts. Pharm Res 26:1986-1994.
15. Woo BH, Kostanski JW, Gebrekidan S, Dani BA, Thanoo BC, DeLuca PP. 2001. Preparation, characterization and in vivo evaluation of 120-day poly (D, L-lactide) leuprolide microspheres. J Control Release 75:307-315.
16. Murty SB, Wei Q, Thanoo BC, DeLuca PP. 2007. In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil processes. AAPS PharmSciTech 5: Article 49.
17. Lucke A, Kiermaier J, Göpferich A. 2002. Peptide acylation by poly (alpha-hydroxy esters). Pharm Res 19:175-181.
18. Na DH, Youn YS, Lee SD, Son MW, Kim WB, DeLuca PP, Lee KC. 2003. Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. J Control Release 92:291-299.
19. Sophocleous AM, Zhang Y, Schwendeman SP. 2009. A new class of inhibitors of peptide sorption and acylation in PLGA. J Control Release 137:179-184.
20. Murty SB, Na DH, Thanoo BC, DeLuca PP. 2005. Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation. Int J Pharm 297:62-72.
21. Park EJ, Tak TH, Na DH, Lee KC. 2010. Effect of PEGylation on stability of peptide in poly (lactide-co-glycolide) microspheres. Arch Pharm Res. 33:1111-1116.
22. Na DH, Lee KC, DeLuca PP. 2005. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm Res 22:743-749.
23. Youn YS, Kwon MJ, Na DH, Chae SY, Lee S, Lee KC. 2008. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. J Control Release 125:68-75.
24. Kim TH, Park CW, Kim HY, Chi MH, Lee SK, Song YM, Jiang HH, Lim SM, Youn YS, Lee KC. 2012. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice. Biol Pharm Bull 35:1076-1083.
25. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. 2007. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 73:84-93.
26. Lucke A, Gopferich A, 2003. Acylation of peptides by lactic acid solutions. Eur JPharm Biopharm 55:27-33.
27. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. 2006. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 49:1608-1611.
28. Kim I, Kim TH, Ma K, Park ES, Oh KT, Lee ES, Lee KC, Youn YS. 2011. A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action. Regul Pept 167:239-245.
29. Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM. 2004. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64:6673-6678.
30. Kozlowski A, Harris JM. 2001. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C. J Control Release 72:217-224.